At ApeX, our mission is simple.  Find safe and effective therapies that will improve the lives of cancer patients.

ApeX Therapeutics is a biotechnology company focused on developing novel compounds to treat cancer.  Our lead drug candidate – APX3330 – targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas and others. Our experienced team of research scientists and clinical specialists will commence studies of APX3330 for the treatment of cancer in 2017.


Our scientific founder, and Chief Scientific Officer, Dr. Mark R. Kelley is the world's leading expert in APE1/Ref-1 protein biology. He is also the Betty and Earl Herr Chair in Pediatric Oncology Research and Professor in the Departments of Biochemistry & Molecular Biology and Pharmacology & Toxicology, Indiana University School of Medicine. He is also the Associate Director of the Herman B. Wells Center for Pediatric Research and for Basic Science Research at the IU Simon Cancer Center. + read more about the ApeX team

Our science is unique and represents first-in-class therapeutic potential. Inhibition of the APE1/Ref-1 redox protein affects signaling pathways critical to cancer cell survival, and ApeX's APX3330 has shown dramatic anti-cancer effect in numerous pre-clinical models of human cancers. Our human studies will evaluate the safety and efficacy of APX3330 in patients with a variety of cancers that express the APE1/Ref-1 protein.
+ read more about the R&D at ApeX
APE1/Ref-1 expressing cancers

Our focus is pancreatic cancer, one of the most deadly cancers in the world.
Our clinical development plan is focused on testing APX3330 against advanced cancers that express the APE1/Ref-1 protein. These advanced cancers constitute areas of high unmet medical need, and include deadly —and dreaded— forms of cancer involving the lung, colon, breast, pancreas, brain and others. The APE1/Ref-1 protein is also expressed in certain pediatric and hematologic cancers, underscoring the importance of this molecular target.
+ Read more about APE1/Ref-1 and ApeX cancer research